Tyfo 200/400 mg tablets represent high-quality ofloxacin antibiotics manufactured to stringent pharmaceutical standards. These tablets provide exceptional broad-spectrum antibacterial activity against gram-positive, gram-negative, and atypical pathogens. Available in two potency options of 200mg and 400mg, these tablets offer healthcare professionals flexible dosing choices for varying infection severities. The formulation ensures consistent quality and reliability, making them a trusted solution for medical practitioners treating bacterial infections across diverse healthcare environments with proven clinical effectiveness and patient safety.

These antibiotics serve essential roles in hospitals, clinics, and healthcare facilities worldwide. Medical professionals utilize Tyfo tablets for treating typhoid fever, urinary tract infections, respiratory tract infections, and sexually transmitted diseases. The pharmaceutical industry values these tablets for their consistent performance in clinical settings, with particular importance in regions combating antibiotic-resistant infections. Healthcare distributors and wholesalers supply these tablets to both public and private healthcare institutions seeking reliable antibiotic solutions with demonstrated efficacy rates and treatment success.

The business value of Tyfo 200/400 mg tablets lies in their proven clinical effectiveness and manufacturing reliability. With 97% clinical cure rates and matching biological cure rates, these products minimize treatment failure risks and support positive patient outcomes. The excellent safety profile and convenient dosing regimen enhance patient compliance, while the demonstrated efficacy against resistant strains provides healthcare providers with confidence in treatment protocols. These factors combine to create a pharmaceutical product that delivers consistent therapeutic results and builds long-term trust among medical professionals and healthcare distributors.

Key Features:
- Broad-spectrum activity against gram-positive, gram-negative and atypical pathogens
- High clinical cure rates demonstrated at 97% effectiveness
- Superior biological cure rates matching clinical efficacy at 97%
- Excellent safety profile with convenient dosing regimen
- Available in two potency options: 200mg and 400mg tablets

Benefits:
- Effective treatment for multiple bacterial infection types
- Reduced treatment failure risk with proven clinical success
- Complete infection resolution with matching clinical and biological cure rates
- Enhanced patient compliance through safety and dosing convenience
- Treatment flexibility with two potency options for varying infection severity